# Low Dose Decitabine in Combination With Tirelizumab Comparison of Tirelizumab in the First-line Treatment of Advanced Esophageal Squamous Cell Carcinoma

> **NCT05638984** · PHASE2 · UNKNOWN · sponsor: **Fudan University** · enrollment: 60 (estimated)

## Conditions studied

- PFS

## Interventions

- **DRUG:** Decitabine Injection
- **DRUG:** tirelizumab

## Key facts

- **NCT ID:** NCT05638984
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-01-01
- **Primary completion:** 2023-12-31
- **Final completion:** 2024-12-31
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2022-12-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05638984

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05638984, "Low Dose Decitabine in Combination With Tirelizumab Comparison of Tirelizumab in the First-line Treatment of Advanced Esophageal Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT05638984. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*